'מערכת אימד'Baraliakos X et.al.; Clin Case Rep. 2022 Jan 20;10(1):e05205.
Abstract
The COVID-19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT-P13 SC, was safe and effective for the treatment of psoriatic arthritis.
Baraliakos X, Tsiami S, Vijayan S, Jung H, Barkham N. Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series. Clin Case Rep. 2022 Jan 20;10(1):e05205. doi: 10.1002/ccr3.5205. PMID: 35079380; PMCID: PMC8777045.